ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical indust.ltd - metformin hydrochloride 850 mg - tablets - metformin - metformin teva is indicated in diet - failed non - insulin dependent diabetic patients especially if overweight either alone as initial therapy or in combination with a sulfonylurea. occasionally as adjuvant therapy in insulin - dependent diabetic patients particularly who are usually obese and not well controlled with insulin.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. ramipril plus is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - hydrochlorothiazide; ramipril - טבליה - ramipril 2.5 mg; hydrochlorothiazide 12.5 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. ramipril plus is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. ramipril plus is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - hydrochlorothiazide; ramipril - טבליה - ramipril 5 mg; hydrochlorothiazide 25 mg - ramipril and diuretics - ramipril and diuretics - essential hypertension. ramipril plus is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 20 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa